On this World Diabetes Day, we join the global effort to raise awareness of the urgent need for improved diabetes care and support the vital work of the International Diabetes Federation (IDF). With over 140 million individuals in China alone affected by diabetes, and millions more worldwide, managing this condition demands constant vigilance and access to effective treatment. At Innovent, we are committed to supporting solutions that not only control blood glucose but also enhance patients' overall health. The recent acceptance of our second NDA for mazdutide represents a step forward in providing patients with a treatment that offers glycemic control, weight reduction, and more. Together, let's work towards a better life for those living with diabetes. #WorldDiabetesDay #DiabetesLife #Mazdutide
Innovent Biologics
制药业
Suzhou,Jiangsu 24,977 位关注者
To develop and commercialize high-quality biopharmaceuticals that are affordable to ordinary people.
关于我们
Innovent is a leading biopharmaceutical company founded in 2011 with the mission to provide high-quality biologics that are affordable to all. The company discovers, develops, manufactures and commercializes innovative medicines that target some of the most intractable diseases. Its pioneering therapies treat cancer, cardiovascular and metabolic, autoimmune and eye diseases. Innovent has launched 11 products in the market. It has 3 new drug applications under regulatory review, 5 assets in Phase III or pivotal clinical trials and 18 more molecules in early clinical stage. Innovent partners with over 30 global healthcare companies, including Eli Lilly, Sanofi, Incyte, Adimab, LG Chem and MD Anderson Cancer Center. Guided by the motto, “Start with Integrity, Succeed through Action,” Innovent maintains the highest standard of industry practices and works collaboratively to advance the biopharmaceutical industry so that first-rate pharmaceutical drugs can become widely accessible. For more information, visit www.innoventbio.com, or follow Innovent on Facebook and LinkedIn.
- 网站
-
http://www.innoventbio.com
Innovent Biologics的外部链接
- 所属行业
- 制药业
- 规模
- 5,001-10,000 人
- 总部
- Suzhou,Jiangsu
- 类型
- 上市公司
- 创立
- 2011
- 领域
- Biologics Manufacturing、Monoclonal Antibodies、Biosimilars和Novel Drugs
地点
Innovent Biologics员工
动态
-
This October 29, on #WorldPsoriasisDay, we embrace the theme "Family," recognizing that psoriasis impacts not just those living with the condition—including over 7 million in China—but also their loved ones who provide essential support. At Innovent, we are dedicated to advancing treatment options with our IL-23p19 inhibitor, Picankibart (IBI112), currently in multiple clinical trials. Our Phase 3 study (CLEAR-1) for moderate to severe plaque psoriasis reached its endpoints in May 2024, and with a recent NDA acceptance in China, we are closer to delivering effective therapies that can enhance the quality of life for both patients and their families. We commend the IFPA for their ongoing efforts to ensure quality care to all individuals affected by psoriasis. Learn more in their report: https://lnkd.in/g_i2TkQm #psoriasis #psoriaticdisease #InnoventBiologics
-
We are pleased to announce the latest positive results from our Phase 2 study of picankibart in patients with plaque psoriasis who had an inadequate response to other biologics. With 64.6% of patients achieving skin clearance or near clearance after 16 weeks, this study brings us one step closer to a new standard of care for moderate to severe psoriasis. https://lnkd.in/gCx5yZse #InnoventBiologics #psoriasis #psoriaticdisease
-
Exciting news from our partner ImmVirX! The first patient has been dosed in a Phase 1b study combining IVX037 with TYVYT® (sintilimab) for advanced colorectal, gastric and ovarian cancers. With four sites already open and more on the way this quarter, we're enthusiastic for this trial to build on the promising effects of monotherapy to bring new options to patients facing these challenging cancers. #InnoventBiologics #ImmVirX #Oncology
-
At #AAO2024, we shared new data from the Phase 2 study of IBI302, a first-in-class bispecific anti-VEGF and anti-complement molecule. The study demonstrated significant improvements in visual acuity and macular anatomy, with the potential for long-interval dosing, suggesting a promising new option for nAMD patients.
-
We are pleased to announce that the Phase 2 study of picankibart (IBI112), the first domestic IL-23p19 drug candidate for ulcerative colitis in China, has successfully met the primary endpoint. This trial marks a significant milestone in evaluating the efficacy and safety of picankibart, offering hope for more innovative treatment options for patients living with moderate-to-severe ulcerative colitis. https://lnkd.in/gWsbeWTr #InnoventBiologics #Autoimmune
-
Innovent is pleased to announce a strategic collaboration with 江苏奥赛康药业股份有限公司 ASK Pharm for limertinib, a third-generation EGFR tyrosine kinase inhibitor (TKI) for lung cancer treatment. Limertinib, an orally administered novel therapy currently under review by China’s NMPA, offers a promising new option for patients with advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC). #InnoventBiologics #Oncology https://lnkd.in/gMhkMmPX
-
The New Drug Application for picankibart injection, a recombinant anti-IL-23p19 antibody, has been accepted by the Center for Drug Evaluation of China's NMPA for the treatment of moderate to severe plaque psoriasis. As the first IL-23p19 antibody to demonstrate over 80% of subjects achieving PASI 90 at 16 weeks, picankibart also offers the longest maintenance dosing interval in its class, delivering significant clinical benefits and improving quality of life for patients. https://lnkd.in/gCjgDQ9N #InnoventBiologics #psoriasis
-
Congratulations to the recipients of the 2024 #LaskerAward for their groundbreaking work in GLP-1-based drugs, transforming obesity treatment worldwide. Their discoveries laid the foundation for a new generation of therapies, including the GLP-1R/GCGR dual agonist Mazdutide, which builds on the successes of earlier treatments, expanding the potential for even greater weight loss and metabolic health improvements. Learn more about the remarkable history and future of GLP-1-based therapies below. The Albert and Mary Lasker Foundation #InnoventBiologics #Mazdutide #glp1 https://lnkd.in/eG3SyZAN https://lnkd.in/g4_8cpmc
-
At #ESMO24, we also had the valuable opportunity to present clinical data for IBI354, a HER2 monoclonal antibody-camptothecin derivative conjugate. With extremely low exposure of free toxin in circulation and an ideal safety profile from pre-clinical and clinical studies, IBI354 shows great promise for patients with advanced tumor types, including breast cancer, ovarian cancer and colorectal cancer. https://lnkd.in/g2D2Qwgk